By Fineline Cube 
China-based Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (SHA: 603707) announced that its Abbreviated New Drug Application (ANDA) for a biosimilar version of Novo Nordisk’s (NYSE: NVO) Victoza (liraglutide) has been approved by the US Food and Drug Administration (FDA). This approval marks the second biosimilar entry in the market following Hybio Pharmaceutical Co., Ltd’s (SHE: 300199) approval in December last year.
Drug Profile
Liraglutide, an analog of human glucagon-like peptide 1 (GLP-1), is indicated for improving blood sugar control in adults and children aged 10 and older with type 2 diabetes. It also reduces the risk of major cardiovascular adverse events in adult patients with type 2 diabetes and cardiovascular disease.
Market Context
Liraglutide works through multiple physiological functions, including glucose-dependent insulin secretion, protection of pancreatic islet β cells, delayed gastric emptying, and reduced appetite. The approval of King-Friend Bio’s biosimilar version further expands treatment options for patients and healthcare providers in the US.-Fineline Info & Tech